Previous studies have highlighted FGFR3 mutations in an array of malignancies, including breast cancer, bladder cancer, prostate cancer, and squamous non-small cell lung carcinoma (sqNSCLC) [52–57]. Here, FGFR3 is linked to urinary bladder carcinoma.